BMH BRÄUTIGAM advises on the acquisition of the CNP Group
BMH BRÄUTIGAM has advised capiton on the acquisition of all shares in the CNP Group.
The transaction is subject to approval by the antitrust authorities.
CNP Group is an international manufacturer and distributor of generic drugs with a focus on anti-infectives. In addition to antibiotics, CNP offers over-the-counter drugs and medical devices. The products are mainly manufactured in the two own production sites in Saarland, Germany. With approx. 400 drug registrations and approx. 251 employees, CNP generates sales of over EUR 40 million in 19 countries.
In cooperation with the management team and experienced industry experts, capiton plans to use the considerable local production capacities and international presence to further strengthen CNP's leadership in its target markets.
Capiton acquires CNP Group together with the management team and industry experts from the founding family. The transaction will be financed from the resources of the Capiton VI fund, with additional funds reserved to finance both organic and inorganic growth initiatives in Germany and abroad.
The lawyers of BMH BRÄUTIGAM have been advising capiton on the acquisition and sale of companies for more than 20 years, most recently the sale of Trioptics GmbH to publicly listed Jenoptik AG and the acquisition of DEC Group.
Team BMH BRÄUTIGAM:
Tina Schmidt (Lead), Jan-Peter Heyer, Till Wansleben (all Private Equity ǀ Corporate/M&A),
Dr. Sylko Winkler, Dr. Manuel Holzmann (Finance)